The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT(2A) and muscarinic receptors

Psychopharmacology

Volumn 141, Issue 3, 1999, Pages 267-278

  Zhang, Wei ^a   Bymaster, Frank P ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Acetylcholine; Antipsychotic; Clozapine; Dopamine; Haloperidol; In vivo; MDL 100907; Muscarinic; Olanzapine; Prefrontal cortex; Risperidone; Serotonin; Sertin dole; Ziprasidone

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHATIDYLINOSITIDE; PILOCARPINE; RACLOPRIDE; RISPERIDONE; SCOPOLAMINE; SEROTONIN; SEROTONIN 2A RECEPTOR; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PHOSPHATIDYLINOSITOLS; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, MUSCARINIC; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0032967875     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050834     Document Type: Article

References (58)

1. Ashby CR Jr, Y WR (1996) Pharmacological actions of the atypical antipsychotic drug clozapine. Synapse 24:349-394
2. Beasley CM, Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167
3. Beasley CM, Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996b) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-123
4. Bolden C, Cusack B, Richelson E (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260:576-580
5. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996a) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
6. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW (1996b) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124:87-94
7. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA (1997) In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 58:28-36
8. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp NW, Shannon HE, Rimvall K, Jeppesen L, Sheardown MJ, Fink-Jensen A, Sauerberg P (1998) Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 795:179-190
9. 3H]-spiperone. Br J Pharmacol 90:467-478
10. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
11. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization (see comments). Am J Psychiatry 148:1474-1486
12. 1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 121:317-322
13. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121-156
14. El-Fakahany EE, Cioffi CL, Abdellatif MM, Miller MM (1986) Competitive interaction of pirenzepine with rat brain muscarinic acetylcholine receptors. Eur J Pharmacol 131:237-247
15. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55:67-69
16. Frazer A (1997) Antidepressants. J Clin Psychiatry 58:9-25
17. Freedman SB, Harley EA, Patel S (1989) Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding. Eur J Pharmacol 174:253-260
18. Fuller RW, Perry KW (1989) Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J Pharmacol Exp Ther 248:50-56
19. Fuller RW, Snoddy HD (1984) Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Neuropharmacology 23:1389-1394
20. Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 77:87-93
21. Fulton B, Goa KL (1997) Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298
22. 3H]quinpirol binding sites in the rat brain. Synapse 14:113-120
23. Goldman-Rakic PS (1996) The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philos Trans R Soc Lond B 351: 1445-1153
24. Goldstein M, Deutch AY (1992) Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J 6:2413-2421
25. 2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95:735-740
26. 1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121: 328-329
27. 3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89: 8155-8159
28. Levey AI (1993) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52:441-448
29. Li XM, Perry KW, Wong DT, Bymaster FP (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136:153-161
30. McQuade RD, Chipkin R, Amlaiky N, Caron M, Iorio L, Barnett A (1988a) Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies. Life Sci 43:1151-1160
31. McQuade RD, Ford D, Duffy RA, Chipkin RE, Iorio LC, Barnett A (1988b) Serotonergic component of SCH 23390: in vitro and in vivo binding analyses. Life Sci 43:1861-1869
32. McQuade RD, Duffy RA, Coffin VL, Barnett A (1992) In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. Eur J Pharmacol 215:29-34
33. Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M (1986) Receptor reserve at striatal dopamine autoreceptor: implications for selectivity of dopamine agonists. Eur J Pharmacol 123:311-314
34. Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3:64-75
35. 2 pKi values. J Pharmacol Exp Ther 251: 238-246
36. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
37. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7
38. Patel S, Freedman SB (1994) The muscarinic receptor agonist L-658,903 modulates the in vivo accumulation of inositol monophosphates in mouse brain. Eur J Pharmacol 267: 329-334
39. 2 binding affinity. Neuropsychopharmacology 1:101-107
40. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-1140
41. Richelson E (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 57:4-11
42. 3 receptor occupancy in vivo measured by radioligand binding. Soc Neurosci Abstr 23:683
43. Schoepp DD, Johnson BG (1988) Selective inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the rat hippocampus by activation of protein kinase C. Biochem Pharmacol 37:4299-4305
44. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73
45. Seeman P, Lee T, Chang-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-718
46. 3) as a target for neuroleptics. Nature 347:146-151
47. 3 dopamine receptor. Arzneimittelforschung 42:224-230
48. 2 receptor antagonists-potential in the treatment of psychiatric disorders. Drug Ther 5:388-409
49. 2 receptors. J Pharmacol Exp Ther 266:1374-1384
50. Taylor N, Beuzen JN, Wesnes K, Wood A (1996) The effects of olanzapine on cognition and psychomotor function in healthy elderly volunteers. Schizophr Res 18:131
51. Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466-474
52. Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998) Depressive signs and symptoms in schizophrenia - a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250-258
53. Umezu K, Moore KE (1979) Effects of drugs on regional brain concentrations of dopamine and dihydroxyphenylacetic acid. J Pharmacol Exp Ther 208:49-56
54. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-669
55. 1 receptors in prefrontal cortex (see comments). Nature 376:572-575
56. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82
57. Wong DT, Bymaster FP, Reid LR, Threlkeld PG (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32:1287-1293
58. Zetterstrom T, Sharp T, Ungerstedt U (1984) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 106: 27-37